Latest news

On World Cancer Day, Adalvo highlights its commitment to expanding access to high-quality oncology treatments. With a portfolio of 37 INNs and a total addressable market of $58 billion (according to...

Adalvo has successfully completed the fixed-dose combination development of Ambrisentan + Tadalafil film-coated tablets and is set to proceed with DCP submission this February, marking a key step towards addressing critical gaps...

Adalvo announces its DCP approval for Adapalene/Benzoyl Peroxide 0.1%/2.5% and 0.3%/2.5% Gel, positioning us as Europe's first and only company to secure approval for both strengths.  Designed for the treatment of...

Adalvo announces its DCP submission for Tacrolimus 0.03% and 0.1% Ointment, a complex, difficult-to-develop formulation designed for effective delivery, and enhancing patient accessibility. With approval anticipated for 2026, this development...

Adalvo announces the launch of the first-ever generic version of Nitrofurantoin to the UK, in collaboration with CNX Therapeutics. Having developed this product in-house, Adalvo are very proud to bring 1st generic...

Adalvo have successfully launched the first-to-market Lisdexamfetamine Oral Solution in Germany, achieved in collaboration with our strategic partner, Aristo Pharma, and co-developers, Labomed and Pharmadata. The formulation is protected by...

Adalvo has submitted the DCP for Palbociclib film-coated tablets on Day 1 following the expiry of Data Exclusivity, reinforcing our commitment to expanding our oncology portfolio. Approval is expected in 2025. Supported...

Adalvo has received DCP approval for Azelastine/Fluticasone nasal spray, strengthening its respiratory portfolio and meeting key market needs.  This approval aligns with  Adalvo’s clearly defined IP pathway, leveraging a complex, difficult-to-develop...

Adalvo has submitted the DCP for Palbociclib film-coated tablets, reinforcing its commitment to expanding its oncology portfolio. Approval is expected in November 2025.  Supported by Adalvo’s focused IP strategy, this submission is...

In recognition of World Diabetes Day, Adalvo highlights its diabetes portfolio, built with a focus on rapid market access and a strong IP strategy.  Our diabetes basket spans a wide range...

Adalvo has received DCP approval for Dapagliflozin film-coated tablets ahead of the standard 210-day timeline, allowing strategic preparation for a Day-1 launch. Backed by a strong IP strategy, Adalvo is...

Adalvo announces the successful multi-country launch of Lisdexamfetamine. To our knowledge, Adalvo was one of the first to introduce this differentiated product in key European markets, showcasing our industry-leading launch...

Adalvo and Myonex announced today the expansion of their existing agreement, under which Myonex is the exclusive provider of Adalvo products for clinical trial use globally. Both parties have now...

Adalvo will submit the DCP for Palbociclib Film-coated Tablets in November 2024.  This submission will strengthen Adalvo’s oncology portfolio, which is backed by our robust IP strategy and aims to guarantee rapid market access....

Adalvo has been recognised with two prestigious awards at the 2024 Global Generics & Biosimilars Bulletin Awards: Business Development of the Year and Value Added Medicine of the Year.  The Business Development...